[
    {
        "pipelineVaccineId": 1,
        "manufacturerId": 9,
        "name": "mRNA-1283",
        "pathogen": [2],
        "status": "Phase 3",
        "licensing_authority": [
            1,
            2,
            4
        ],
        "milestones": {
            "description": "Next-generation COVID-19 vaccine designed for improved stability at refrigerator temperatures.",
            "expected_filing": "2024",
            "key_trial_results": "Phase 3 study ongoing; data expected in early 2024"
        }
    },
    {
        "pipelineVaccineId": 2,
        "manufacturerId": 9,
        "name": "mRNA-1083",
        "pathogen": [2,8],
        "status": "Phase 3",
        "licensing_authority": [
            1,
            2
        ],
        "milestones": {
            "description": "Combination vaccine for both COVID-19 and seasonal influenza, targeting annual immunization.",
            "expected_filing": "2024",
            "key_trial_results": "Positive results in early trials; ongoing Phase 3 with data anticipated in 2024."
        }
    },
    {
        "pipelineVaccineId": 3,
        "manufacturerId": 9,
        "name": "mRNA-1010",
        "pathogen": [8],
        "status": "Phase 3",
        "licensing_authority": [
            1,
            2
        ],
        "milestones": {
            "description": "Standalone seasonal flu vaccine aimed at improved protection over standard flu vaccines.",
            "expected_filing": "2024",
            "key_trial_results": "Met primary endpoints in Phase 3 trials; showed superior immune response compared to Fluzone HDÂ®."
        }
    },
    {
        "pipelineVaccineId": 4,
        "manufacturerId": 9,
        "name": "mRNA-1345",
        "pathogen": [1],
        "status": "Filed for approval",
        "licensing_authority": [
            1
        ],
        "milestones": {
            "description": "RSV vaccine for prevention in older adults, particularly effective in preventing RSV-related lower respiratory disease.",
            "expected_approval": "First half of 2024",
            "key_trial_results": "Filed with strong Phase 3 efficacy data."
        }
    },
    {
        "pipelineVaccineId": 5,
        "manufacturerId": 9,
        "name": "mRNA-1647",
        "pathogen": [19],
        "status": "Phase 3",
        "licensing_authority": [
            1,
            2
        ],
        "milestones": {
            "description": "Vaccine for prevention of CMV, a leading cause of birth defects.",
            "expected_filing": "Late 2024",
            "key_trial_results": "Phase 3 interim analysis expected by end of 2024."
        }
    },
    {
        "pipelineVaccineId": 6,
        "manufacturerId": 9,
        "name": "mRNA-1403",
        "pathogen": [24],
        "status": "Phase 1",
        "licensing_authority": [
            1
        ],
        "milestones": {
            "description": "Vaccine targeting norovirus, a leading cause of acute gastroenteritis worldwide.",
            "expected_next_phase": "2024",
            "key_trial_results": "Phase 1 trial showed robust immune responses; pivotal Phase 3 trials expected to begin soon."
        }
    },
    {
        "pipelineVaccineId": 7,
        "manufacturerId": 9,
        "name": "mRNA-4157",
        "pathogen": [25],
        "status": "Phase 3",
        "licensing_authority": [
            1
        ],
        "milestones": {
            "description": "Personalized cancer vaccine in partnership with Merck, designed to improve outcomes in combination with Keytruda.",
            "expected_filing": "2025",
            "key_trial_results": "Phase 3 trials ongoing with promising results in early trials."
        }
    }
]